ArticleBMC infectious diseases2006
Mediterranean spotted fever: clinical and laboratory characteristics of 415 Sicilian children.
Article in BMC infectious diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 81 citations in OpenAlex.
- Randomized Trial of Clarithromycin for Mediterranean Spotted Fever.Antimicrobial agents and chemotherapy · 2015Trial
- A rare case of spotted fever group rickettsiosis in southern Iran: diagnostic challenges and review.Infection · 2026Review
- Rickettsia africae infections in sub-Saharan Africa: A systematic literature review of epidemiological studies and summary of case reports.Tropical medicine & international health : TM & IH · 2024Review
- Mediterranean spotted fever with multiorgan involvement.BMJ case reports · 2022Article
- IL-1 Superfamily Member (Biomolecules · 2022Article
- Natural Mediterranean Spotted Fever Foci, Qingdao, China.Emerging infectious diseases · 2022Article
- Investigation ofPathogens (Basel, Switzerland) · 2022Article
- Rickettsiosis with Pleural Effusion: A Systematic Review with a Focus on Rickettsiosis in Italy.Tropical medicine and infectious disease · 2022Review
- High diversity ofFrontiers in microbiology · 2022Article
- Canine and Feline Parasitology: Analogies, Differences, and Relevance for Human Health.Clinical microbiology reviews · 2021Review
- Mediterranean Spotted Fever: Current Knowledge and Recent Advances.Tropical medicine and infectious disease · 2021Review
- Review
- Expansion of Tick-Borne Rickettsioses in the World.Microorganisms · 2020Review
- Epidemiology, Clinical Aspects, Laboratory Diagnosis and Treatment of Rickettsial Diseases in the Mediterranean Area During COVID-19 Pandemic: A Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2020Review
- Molecular confirmation & characterization ofThe Indian journal of medical research · 2020Article
- Rickettsial infections of the central nervous system.PLoS neglected tropical diseases · 2019Review
- Myocarditis in Mediterranean spotted fever: a case report and a review of the literature.JMM case reports · 2016Article
- Acute febrile illness is associated with Rickettsia spp infection in dogs.Parasites & vectors · 2015Article
- Mediterranean spotted fever: case series of 24 years (1989-2012).SpringerPlus · 2015Article
- Update on tick-borne rickettsioses around the world: a geographic approach.Clinical microbiology reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMediterranean spotted fever (MSF) is an acute febrile, zoonotic disease caused by Rickettsia conorii and transmitted to humans by the brown dogtick Rhipicephalus sanguineus. Nearly four hundred cases are reported every year (mainly from June to September) on the Italian island of Sicily. The aim of the study was to analyze the clinical and laboratory characteristics of patients with MSF and the efficacy of the drugs administered.
methodsOur study was carried out on 415 children with MSF, during the period January 1997-December 2004, at the "G. Di Cristina" Children's hospital in Palermo, Sicily, Italy. On admission patients' clinical history, physical and laboratory examination and indirect immunofluorescence antibody test (IFAT) for Rickettsia conorii were performed. Diagnosis was considered confirmed if the patients had an MSF diagnostic score greater than or equal to 25 according to the Raoult's scoring system. All patients were treated with chloramphenicol or with macrolides (clarithromycin or azithromycin).
resultsFever, rash and tache noire were present in 386 (93%), 392 (94.5%) and 263 (63.4%) cases respectively. Eighteen (4.6%) children showed atypical exanthema. Chloramphenicol and newer macrolides all appeared to be effective and safe therapies.
conclusionClinical features of 415 children with MSF were similar to those reported by other authors except for a lower incidence of headache, arthralgia and myalgia and a higher frequency of epato-splenomegaly. Concerning therapy, clarithromycin can be considered a valid alternative therapy to tetracyclines or chloramphenicol especially for children aged < eight years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.